Liquidia Q2 2026 Earnings Report

Liquidia EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.76
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Liquidia Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $168.48 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Liquidia Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 12, 2026
• Conference Call Time: 8:30AM ET

Liquidia (NASDAQ:LQDA) Technologies, Inc. is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH). LIQ861 aims to offer a more convenient and potentially more consistent dosing approach compared with current liquid-based nebulized therapies. Besides PAH, Liquidia is exploring additional indications and dosage forms to expand the use of its PRINT platform, including collaborations focused on vaccine adjuvants and other respiratory applications.

Liquidia Technologies was founded to translate advanced particle-engineering science into therapeutic benefit and has assembled a team with experience in respiratory drug development, regulatory affairs and clinical operations. The company conducts clinical research primarily in the United States, and it plans to pursue regulatory filings in major markets following the completion of pivotal studies. Under the leadership of President and CEO Chris Critelli, Liquidia continues to advance its pipeline toward potential commercialization.